Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00081487" target="_blank" >RIV/65269705:_____/24:00081487 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/24:A25039MD RIV/00216208:11110/24:10492706 RIV/61989592:15110/24:73626901 RIV/00098892:_____/24:10158854 and 2 more

Result on the web

<a href="https://www.nejm.org/doi/10.1056/NEJMoa2400712" target="_blank" >https://www.nejm.org/doi/10.1056/NEJMoa2400712</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa2400712" target="_blank" >10.1056/NEJMoa2400712</a>

Result language

angličtina

Original language name

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Original language description

BACKGROUND Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. RESULTS A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P&lt;0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P=0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P=0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30218 - General and internal medicine

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

1533-4406

Volume of the periodical

391

Issue of the periodical within the volume

17

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

1597-1609

UT code for WoS article

001409462600001

EID of the result in the Scopus database

2-s2.0-85196303104